m6A-centered Drug Response Information
General Information of the Drug (ID: M6APDG02918)
| Name |
FV-100
|
||||
|---|---|---|---|---|---|
| Synonyms |
CF-1001; CF-1094; CF-1368; CF-1369; CF-1449; CF-1452; CF-1698; CF-1712; CF-1743; CF-1821; CF-1835; CF-1837; CF-1838; CF-1851; CF-2004; CF-2160; CF-2161; CF-2200; BCNAs (antiviral), FermaVir Pharmaceuticals; Bicyclic nucleoside analogs (VZV infection), FermaVir; Bicyclic nucleoside analogs (VZV infection), Inhibitex; Antivirals (nucleoside derivatives), Welsh School of Pharmacy/Rega; BCNAs (antiviral), Rega/Welsh School of Pharmacy; Bicyclic nucleoside analogs (antiviral), Rega/Welsh School of Pharmacy
Click to Show/Hide
|
||||
| Status |
Phase 3
|
||||
| Structure |
 |
||||
|
3D MOL
|
|||||
| Formula |
C27H36ClN3O6
|
||||
| InChI |
1S/C27H35N3O6.ClH/c1-4-5-6-7-17-8-10-18(11-9-17)21-12-19-14-30(27(33)29-25(19)36-21)23-13-20(31)22(35-23)15-34-26(32)24(28)16(2)3;/h8-12,14,16,20,22-24,31H,4-7,13,15,28H2,1-3H3;1H/t20-,22+,23+,24-;/m0./s1
|
||||
| InChIKey |
CAHTYTZOAVUCIU-ZMQZINMSSA-N
|
||||
| PubChem CID | |||||
| TTD Drug ID | |||||
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Thymidine kinase 1 (TK1)
Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||
Methyltransferase-like 14 (METTL14)
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [1], [2] | ||